Global Plasma Protein Therapeutics Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Product Type, Application & Region - Industry Forecast (2024 to 2029)

Updated On: January, 2024
ID: 205
Pages: 171

Global Plasma Protein Therapeutics Market Size (2024 to 2029)

The global plasma protein therapeutics market is estimated to grow to USD 47586 million by 2029 from USD 30970 million in 2024, growing at a CAGR of 8.97% during the forecast period.

Plasma is a protein-rich fluid crucial in clotting and providing immunity to diseases. By isolating the proteins from plasma, they can be used for medical therapies, including autoimmune, immune deficiencies, neurological and bleeding disorders. Plasma protein therapies treat well-defined medical conditions by replacing the deficient or missing proteins in plasma. Plasma protein therapeutics involves biological medicines, either infused or injected, to treat life-threatening, chronic, and genetic diseases. Plasma protein therapies help treat unique medical conditions caused by a missing or defective protein in the body's plasma by replacing them, encouraging a healthy life for the patient. 


The growing use of plasma protein in medical applications and technological advancements are propelling the plasma protein therapeutics market growth.

According to data published by the World Health Organization (WHO), more than 50% of blood donors worldwide are from developed countries, accounting for 18% of the population. The growing awareness among people regarding blood donations and the increasing number of initiatives by various governments are favoring the growth of the plasma protein therapeutics market. In addition, factors such as the rising prevalence of life-threatening diseases involving the immune or neurological systems and other infectious diseases such as Rabies, Tetanus, Hepatitis A&B, and varicella are propelling the plasma protein therapeutics market.

Furthermore, growth opportunities for the market lie in the increasing use of these plasma proteins in pharmaceuticals, which are effectively used to treat diseases such as hemostasis. Growing awareness of the utilization of various components in the laboratories, which are highly effective and promote a modernized way of treatment procedures, is significantly influencing the demand of the Global Plasma Protein Therapeutics Market. The plasma protein therapeutics market is also driven by the rising incidences of genetic disorders worldwide. The trend toward detecting diseases at an early stage by diagnosing them as early as possible is enhancing the market's growth rate. Furthermore, the demand for targeted therapies has been growing tremendously for the past two decades, which is estimated to promote the market's growth rate. Also, these therapies offer custom-made treatment procedures for the patients, specifically to meet the desired outcomes. The factor mentioned above also fuels the global plasma protein therapeutics market growth. 


Stringent government policies, reimbursement issues, and manufacturing complexity are majorly hindering the growth of the plasma protein therapeutics market. 

Additionally, there are certain limitations to plasma protein therapy, like patient plasma not having any neutralizing antibodies, high infusion rates required for successful procedures, lengthy administration periods, and the presence of plasma thinning Abs, etc., leading to drawbacks for the market.

Impact Of COVID-19 On The Global Plasma Protein Therapeutics Market

COVID-19 is an unprecedented global public health emergency that has impacted almost every sector, with long-term effects on industry development. Various inherited, chronic, life-threatening, and rare disorders are treated with plasma protein therapies. Plasma is a protein-rich fluid that plays a significant role in clotting and disease immunity. Therefore, the proteins can be isolated from plasma and used for medical treatments. In the case of COVID-19, government agencies in different countries, research institutes, and several biotech and pharmaceutical companies are concentrating on efficient and rapid technologies for the rapid diagnosis of COVID-19 and the development of vaccines and new therapeutics to combat the current situation. The current COVID-19 pandemic has temporarily halted plasma donation worldwide, which could affect the demand for plasma protein therapeutics. However, researchers concentrate their efforts on plasma-based therapeutics to see whether they can help treat the COVID-19 virus. Due to such factors, the plasma protein therapeutics market had moderate growth during the COVID-19 pandemic. However, considering the reduced impact of COVID-19, the global market for plasma protein therapeutics is expected to showcase a healthy CAGR during the forecast period.




Market Size Available

2022 to 2028

Base Year


Forecast Period

2023 to 2028

Segments Covered

By Type, Application, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis; DROC; PESTLE Analysis; Porter’s Five Forces Analysis, Competitive Landscape; Analyst Overview of Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa

Market Leaders Profiled

Baxter, CSL Behring, Biotest, China Biologics, Grifols, Kedrion, Octapharma, Shire Plc, and Chengdu Inst



Global Plasma Protein Therapeutics Market Analysis By Type

The albumin segment accounted for the major share of the global market in 2023. The segment’s domination is expected to continue during the forecast period owing to the rising prevalence of quality treatment procedures. In addition, the growing focus on implementing various therapies for infectious diseases and lowering the complexity of real-time applications are promoting the segment’s growth.

However, the other plasma protein types, such as immunoglobulins, factor VIII and coagulation factors segments, are expected to register healthy growth in the coming years due to the growing applications of the segments. For example, the growing cases of immunodeficiency diseases are leading to a rise in the demand for immunoglobulins leading to market revenue and rising cases of hemophilia patients requiring factor VIII, leading to demand for the segment. Furthermore, replacement surgeries use alpha-1 proteinase inhibitors leading to demand. 

Global Plasma Protein Therapeutics Market Analysis By Application

The hemophilia segment accounted for the major share of the plasma protein therapeutics market in 2023 and the domination of the segment is likely to continue during the forecast period owing to the increasing geriatric population and a growing number of patients with life-threatening diseases. In addition, private and public sectors' rising investments in hospital construction are favoring segmental growth. Furthermore, changes in food habits and adopting sedentary lifestyles, especially in urban areas, fuel the segment’s growth rate. 

On the other hand, the PID segment is also expected to grow significantly during the forecast period due to increasing cases of primary immunodeficiency disorders going unreported. Additionally, the growing adoption of immunoglobulins and high-cost treatment procedures for more than 200 rare and chronic immunodeficiency diseases are contributing to the growth of the segment in the global market. 


North America accounted for the most dominant share of the worldwide market in 2023. The region’s dominance is anticipated to continue during the forecast period owing to the growing capital income in developed and developing countries, emerging modern technologies, and the launching of innovative therapies. In addition, 4.5 million Americans require blood transfusions annually, according to statistics from community blood centers for 2020. The prevalence and incidence of neurological and autoimmune illnesses are rising. In addition, even though the senior population is expanding and the healthcare system is well-established, 43,000 pints of blood are utilized daily in the United States and Canada, keeping the supply of high-quality source plasma at an average of one in seven patients who enter a hospital.

In 2023, Europe accounted for a substantial share of the global market owing to the rising support from government bodies in changing schemes and implementing reimbursement in favor of the end-users.

The Asia-Pacific had the fastest growth rate in the past decade and will continue the same flow for years. India and China are major countries contributing to the highest shares of market growth. Increasing chronic and infectious diseases and the growing geriatric population are significant factors for this region's development. Additionally, the growing demand for albumin in Asian countries and the rising immunoglobulin utilization help further expand the market.


Companies that are playing a dominating role in the global plasma protein therapeutics market in this report are Baxter, CSL Behring, Biotest, China Biologics, Grifols, Kedrion, Octapharma, Shire Plc, and Chengdu Inst.


  • In January 2023, to offer breakthrough minor molecule protein degrader medications, Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical business, is pursuing targeted protein degradation (TPD). The Phase 1 trial of Kymera's lead program, KT-474 (SAR444656), showed fidelity of translation from healthy volunteers to patients, a favorable safety profile, and clinical impact in complex inflammatory diseases like hidradenitis suppurativa (HS) and atopic dermatitis. 
  • In August 2018, in the U.S., Grifols S.A. acquired 24 plasma donor centers, which have thrived in the company's position, and Biotest AG will operate these companies to improve shares.
  • In March 2018, the first immunoglobulin therapy received approval from the food and drug administration (FDA) and was developed by CSL’s Hizentra. It is highly used to treat chronic inflammatory demyelinating polyneuropathy (CIDP).
  • In June 2016, Baxalta was acquired by Shire Plc, which enhanced its shares and developed its product portfolio. The main aim is to create a strong pipeline for the treatment of varied diseases which rarely occur.


This report on the global plasma protein therapeutics market has been segmented & sub-segmented based on type, application, and region.

By Type

  • Albumin
  • Coagulation Factors
  • Alpha-1 proteinase inhibitor
  • Others

By Application

  • Hemophilia
  • Primary Immunodeficiency Disorder
  • Idiopathic Thrombocytopenic Purpura
  • Secondary Immunodeficiency
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

Please wait. . . . Your request is being processed

Frequently Asked Questions

How much was the global plasma protein therapeutics market worth in 2021?

The global plasma protein therapeutics market size was valued at USD 23936 million in 2021.

Does this report include the impact of COVID-19 on the plasma protein therapeutics market?

The impact of COVID-19 on the plasma protein therapeutics market is analyzed and included in this report.

Who are the key players in the plasma protein therapeutics market?

Baxter, CSL Behring, Biotest, China Biologics, Grifols, Kedrion, Octapharma, Shire Plc, and Chengdu Inst are some of the notable players in the plasma protein therapeutics market.

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1800

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample